Progressive multifocal leukoencephalopathy associated with ruxolitinib

New England Journal of Medicine

Volumn 369, Issue 2, 2013, Pages 197-198

  Wathes, Rowan ^a   Moule, Simon ^b   Milojkovic, Dragana ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b Northwick Park Hospitals NHS Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; RUXOLITINIB;

AGED; ATAXIA; BLOOD CELL COUNT; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COGNITIVE DEFECT; CONFUSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHASIA; FACIAL NERVE PARALYSIS; GAIT DISORDER; HUMAN; LETTER; LYMPHOCYTE COUNT; MALE; MYELOFIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

EID: 84880323178     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1302135     Document Type: Letter

References (4)

1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebocontrolled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
2. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70.
3. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80.
4. Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012;78:1390-3.